In recent years nitric oxide (NO) has gained increasing recognition as an important neurotransmitter and cell signaling molecule with a broad range of functions in the lower urinary tract. This review discusses recently published data related to the physiologic and pathophysiologic roles of NO and nitric oxide synthase (NOS) in the female lower urinary tract.
Introduction
Nitric oxide (NO) has been shown to play important physiologic roles in various organs for regulation of vascular smooth muscle tone and proliferation, and in neurotransmission of the peripheral and central nervous systems. NO was originally termed 'endothelium derived relaxing factor' (EDRF). The mechanism underlying EDRF-induced relaxation of vascular smooth muscle was found to be primarily calcium dependent, with cGMP identified as the second messenger. Later, it became clear that the EDRF synthesized by endothelial cells was in fact NO and was dependent on the presence of L-arginine [1] . In recent years NO has gained increasing recognition as an important neurotransmitter and cell mediator with a broad range of functions in the lower urinary tract. Elucidation of the physiologic role of NO and nitric oxide synthase (NOS) is not only of research interest but it may also provide a basis for therapeutic interventions in patients with lower urinary tract dysfunction.
Mechanism of nitric oxide synthase/nitric oxide-mediated actions in the lower urinary tract NO is synthesized by a family of enzymes known as NOSs. Three distinct isoforms of NOS, namely endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS), have been described, based on the cells in which they were first identified, isolated, purified, and cloned [2] . The eNOS isoform was first described in epithelial cells of large vessels and the nNOS isoform was first described in neuronal tissues, although both are now known to be present in many other cell types. Both eNOS and nNOS are normal constituents of cells and are termed constitutive. They are activated by binding to calmodulin, and hence they are regulated by physiologic concentrations of calcium. The third isoform, iNOS, was originally identified in activated macrophages and is induced by inflammatory mediators in a number of cell types. The activity of iNOS is not regulated by intracellular calcium because the latch domain of the enzyme has a high affinity for calmodulin; thus, calmodulin is constitutively bound and unaffected by further changes in intracellular calcium. Under certain circumstances the levels of expression of eNOS and nNOS are also inducible.
The NOS isoforms are the products of separate genes, located on human chromosome 7 for eNOS, chromosome 12 for nNOS, and chromosome 17 for iNOS [2] . The NOS isoforms vary considerably in terms of subcellular location, structure, kinetics, regulation, and function. The eNOS is membrane-associated, whereas nNOS and iNOS are cytosolic. All three isoforms have been identified in the lower urinary tracts of several animal species, and in humans [3].
In the presence of oxygen and the reduced form of nicotinamide adenine dinucleotide phosphate, NOS catalyzes the conversion of L-arginine to NO and Lcitrulline. NO is not prestored but is produced on demand, and then diffuses freely from its site of production to adjacent target tissues. It has a short halflife, in the order of seconds, and it is inactivated by reacting with oxygen to form nitrite and nitrate. The exact mechanism by which NO mediates smooth muscle relaxation in the lower urinary tract is not fully understood. After local production, NO diffuses to target tissues and binds to the heme moiety of guanylyl cyclase. This step activates guanylyl cyclase, which then catalyzes the formation of cGMP from GTP. The NO-induced relaxation is mediated by cGMP [3,4 . . ,5]. In some cases NO can also act independently of the cGMP pathway, an example of which is the cytotoxic action of macrophage-derived NO on tumor cells and other tissues components. NO reacts with superoxide to produce peroxynitrite, which may contribute to tissue damage in inflammation and ischemia/reperfusion injury [3].
Distribution of nitric oxide synthase in the lower urinary tract
Expressions of eNOS, nNOS and iNOS, have been demonstrated in various tissues of the lower urinary tract in animals and humans. In addition to its relaxation effects on bladder and urethra, NO also serves as a neurotransmitter in the lower urinary tract.
Bladder NOS activity has been identified in the urothelium, smooth muscle, striated muscle, nerves, and blood vessels of the lower urinary tract of animal models. Detrusor muscle has fewer nitrinergic innervations and it is less sensitive to the action of NO as compared with the urethra. Exposure of rat, rabbit, and pig bladder preparations to NO or NO donors produced lesser relaxation than observed in urethral preparations [3,4 . . ]. Detrusor smooth muscle cells may also be less sensitive to the effects of cGMP than the urethral sphincter. The different distributions of NOS in the bladder and proximal urethra were investigated in rabbit [6] . In the bladder the total NOS activities were mainly detected in the mucosa, whereas in the urethra NOS activities were distributed throughout the mucosa and muscularis. However, in bladder tissues obtained from 18 humans the detrusor muscle was recognized as an important site of eNOS expression, whereas the urothelium had only minor eNOS activity [7] . nNOS expression was identified only in nitrinergic fibers of the submucosal surface and between muscle cells [7] .
There is also conflicting evidence for the role played by NO in the detrusor muscle. In animal models NO has been shown to induce detrusor smooth muscle relaxation, and upon administration of NOS inhibitors, either by the systemic or by the intravesical route, the bladder capacity was decreased and the magnitude of bladder contractions was increased [3,4 . . ]. Although NOmediated relaxation of smooth muscle in lower urinary tract has been suggested, Theobald [8 . . ] recently showed that inhibitions of eNOS and nNOS produce opposing effects in the cat bladder. Inhibition of eNOS significantly decreased micturition volume threshold and increased frequency of small bladder contractions, whereas inhibition of nNOS had opposite effects. Recently, a study conducted in guinea pig bladder [9] showed that the detrusor muscle did not respond with a rise in cGMP when exposed to sodium nitroprusside, a NO donor. This finding indicates that a direct NO/ cGMP-dependent relaxation of the bladder detrusor is unlikely. Further studies are needed if we are to elucidate fully the role played by NO and nitrinergics in the bladder.
b-Adrenoreceptor agonists have been shown to stimulate eNOS in urothelium of rat bladder and increase intracellular calcium, which triggers production of NO [10]. Expression of iNOS in rat bladder smooth muscle cells was induced after stimulation with cytokines that are known to be produced during urinary tract infection [11] . NO may play a role in regulating the blood supply to the detrusor during the voiding and filling phases. NO also plays a role in bladder ischemic injury because the effects of bladder ischemic injury can be reversed by NOS inhibitors. Treatment with N G -nitro-L-arginine methyl ester, a NOS inhibitor, significantly reduced the extent of reperfusion injury and reduced apoptosis induced by ischemia/reperfusion in rat bladders [12] . Furthermore, NO regulates bladder mucosal and muscle perfusion in an inverse relationship to the intravesical pressure. These findings suggest that NO may play a role in lower urinary tract dysfunction caused by reduction in blood flow to the bladder and urethra during and after pelvic surgical trauma.
Urethra and bladder neck
Immunohistochemical studies in both guinea pigs and humans have shown that there is a prominent induction of cGMP in the proximal urethral smooth muscle by NO, but cGMP could not be induced in the detrusor muscle despite significant expression of NOS. Instead, the interstitial cells of the detrusor exhibited intense cGMP immunoreactivity. These cells appear to be the predominant target of NO in the detrusor muscle [3,4 . . ]. NO is an important mediator in the relaxation of urethra and urethral sphincter, and this relaxation is associated with increased cGMP levels. NO donors relax the urethra and bladder neck, whereas NOS inhibitors such as N-nitro-L-arginine block the relaxation. The inhibition of NO production by systemic administration of NOS inhibitor abolishes urethral smooth muscle relaxation [13] . Administration of NOS inhibitor (N-nitro-L-arginine) stimulates detrusor hyperactivity and inhibits urethral smooth muscle relaxation during micturition. Systemic infusion of NO donors increases urethral relaxation and decreases baseline urethral pressure, whereas topical intraurethral application of NO donors induces urethral smooth muscle relaxation without affecting bladder smooth muscle function [3,4 . . ]. These findings suggest that detrusor instability secondary to bladder outlet obstruction (BOO) may be caused by the lack of NO bioactivity at the bladder outlet, and NO donors may serve as effective treatments for sphincter spasticity and obstruction [14] .
A functional urodynamic study conducted to assess the effect of the NO donor isosorbide dinitrate on resting tone and contractile behavior of the external urethral sphincter in healthy humans was recently reported [15 . ]. Sublingual administration of isosorbide dinitrate significantly reduced the resting pressure of the external urethral sphincter for at least 1 h, along with a significantly decreased maximal contractile strength. The fatigue properties of the external urethral sphincter did not change significantly with administration of NO donor.
NO also plays a role in the control of intramural striated muscle of the female urethra. Imunoreactivities of NOS were detected in the sacrolemma of the striated muscle fibers in female urethra [16 . ]. The distribution of the nNOS isoform in the external urethral sphincter was investigated in an animal model, and nNOS was detected in the sacrolemma of some but not all striated fibers [17] . The nNOS isoform apears to be concentrated at the neuromuscular junction and present in nerve fibers and intramural ganglia, with the density of innervation decreased toward the distal part of the urethral sphincter. The physiologic relevance of these findings remains to be determined. Neurons that innervated smooth muscle of the urethra contain NO, and periurethral denervation resulted in impaired urethral smooth muscle relaxation in rats [18] . NOS is also detected in the connective tissues and endothelium of small and large arteries supplying the lower urinary tract. The effect of ischemia on NO-mediated urethral relaxation was investigated in rabbit models, and the results suggest that the impaired urethral relaxation is closely related to the decreased NOS activity in the urethra [19] . Neurotransmission NO appears to play an important role in nonadrenergic, noncholinergic neurotransmission in a variety of organ systems, including the lower urinary tract. Studies in animal models using immunohistochemistry to identify NOS demonstrated that NOS-containing fibers in the major pelvic ganglion project mainly to urethra, with minimal innervations to the detrusor muscle. NOcontaining nerves that supply the lower urinary tract either originate from or pass through the pelvic ganglia. In rats, stimulation of the parasympathetic input to the urethra elicits NO-dependent urethral smooth muscle relaxation. Furthermore, removal of the major pelvic ganglia abolishes NO-dependent urethral smooth muscle relaxation [3,4 . . ]. Similar findings were reported in humans. NOS immunoreactivity has also been demonstrated in the striated muscle of urethral sphincter in humans [3,4 . . ].
The density of NOS-containing nerves and NOS enzyme activity are significantly greater in the bladder neck and urethra than in the detrusor muscle. Because the inhibitory effects of NO correlate with the density and distribution of NOS-containing nerves and NOS activity, smooth muscle relaxation mediated by NO is significantly greater in the urethra than in the bladder [3,4 . . ]. Primary afferent nerves seen beneath and penetrating the urothelium are also considered a possible source of NO. Apart from acting as a primary inhibitory neurotransmitter, NO may also serve as a neuromodulator by virtue of its close association with the cholinergic and sympathetic neuronal systems. It may play a role in regulating the response of the detrusor to other neurotransmitters. A study conducted in rabbits [20] suggested that a NO-mediated mechanism exists that inhibits acetylcholine release from cholinergic nerve endings in the bladder.
Nitric oxide synthase/nitric oxide in overactive bladder and detrusor instability
Detrusor instability is defined by involuntary detrusor contractions during the filling phase. Although the etiology of detrusor instability can be considered under two broad categories, myogenic and neurogenic, the precise mechanism of detrusor instability is poorly understood. NO is thought to play a role in bladder overactivity. Inactivation of the gene encoding cGMPdependent protein kinase I in mice results in prevention of urethral smooth muscle relaxation and development of bladder hyperactivity [3,4 . . ]. These findings strongly suggest that bladder instability may be associated with impairment in the NO signaling pathway, and that manipulating this pathway may effectively treat overactive bladder and BOO.
In a prospective, randomized study conducted in 31 patients with urodynamically proven idiopathic detrusor overactivity [21 . ], intravesical administration of the NO donor sodium nitroprusside did not have any effect on uninhibited bladder contraction. In another study in 14 children with detrusor instability [22] , bladder biopsies were obtained and total nitrite levels were determined. The tissue levels of NO in these children were lower than those in six children with normal bladder activity, suggesting that decreased NO production plays a role in the pathophysiology of detrusor instability. The contribution of cerebral NO to bladder overactivity after cerebral infarction was investigated in rats, and the results indicate that supraspinal NO plays an important role in bladder overactivity after cerebral infarction but does not affect normal micturition [23] . There may be a central mechanism that is sensitive to NO in bladder overactivity after cerebral infarction.
A pilot phase II clinical trial of NO-flurbiprofen in patients with neurogenic bladder instability was recently performed [24] . This new NO-releasing drug combines the effects of a prostaglandin synthesis inhibitor and NO releasing moiety on detrusor instability. Prostaglandins can directly cause contraction of bladder muscle and sensitize afferent C-fibers. Nine patients exhibited improvement in both urodynamic parameters (bladder capacity and compliance) and clinical symptoms (urinary urgency, frequency, and leakage). This new class of drug may have potential in the treatment of bladder overactivity.
Nitric oxide synthase/nitric oxide in bladder outlet obstruction and spinal cord injury
BOO is more common in elderly males than in females because of the common condition of benign prostatic hyperplasia. Patients with BOO usually suffer from increasing amounts of residual urine and overflow incontinence. These symptoms may be related to impairment in detrusor contractility and to the detrusor's inability to compensate for BOO. However, the compensatory changes in bladder function due to BOO are poorly understood. Some investigators have reported that increased intravesical pressure in BOO is associated with decreased bladder blood flow [25] . A study in rats indicated that L-arginine, a precursor of NO synthesis, has beneficial effects in bladder dysfunction in BOO because of its ability to increase NO levels and therefore the rate of blood flow to the obstructed bladder [25] . In another study in rats and mice [26 . ], partial BOO induced the expression of iNOS in the bladder. Inhibition of iNOS activity with aminoguanidine in these animals significantly attenuated the increase in bladder size and the number of spontaneous bladder contractions while decreasing bladder fibrosis. The changes in nNOS in micturition reflex pathway in rat models with BOO were studied [27] . The results showed an increase in bladder afferent neurons expressing nNOS immunoreactivity in L6 and S1 dorsal root ganglia, and the increase in nNOS in S1 dorsal root ganglia was significantly greater in female than in male rats. Johansson et al. [28] showed that nNOS activity in rat bladder decreased after obstruction, as confirmed by Western blot analysis. They also showed that iNOS activity increased after bladder obstruction, with iNOS expression primarily in urothelial and inflammatory cells. These results indicate that NOS may play an important role in the progression of pathologic changes of the bladder secondary to BOO.
Patients with spinal cord injuries lose the reflex reciprocal relationship between bladder and external sphincter function. In these patients, the urethral sphincter contracts at the same time as when the bladder contracts, thereby causing detrusor-external sphincter dyssynergia (DESD), which leads to ineffective bladder emptying, recurrent urinary tract infections, hydronephrosis, and renal failure. In a study conducted in 37 spinal cord injured patients with a chronic indwelling urinary catheter, iNOS was detected in macrophages localized to the lamina propria of the inflamed bladder but there was no iNOS expression in urothelial cell layers [29] . However, Romih et al. [30 . ] reported that iNOS was upregulated in bladder urothelium samples from 15 male patients with BOO secondary to benign prostatic hyperplasia. The upregulation of iNOS was detected only in the undifferentiated urothelial zones lacking uroplakins and asymetric unit membrane, suggesting focal compromise of the blood-urine permeability barrier.
NO may have a complex effect in BOO. In the early stage of BOO, the NO production could potentially protect the bladder against ischemic damage by inducing vasodilatation, leading to increased blood flow to the bladder. However, during the decompensation phase, sustained production of NO can form oxidative products, which are carcinogenic to the bladder. Excess production of NO also serves as a source of peroxynitrite and causes oxidative injury associated with BOO. NO donors have been proposed as an alternative to external sphincterotomy to lower urethral pressures in spinal cord injury patients with DESD [31, 32] . NO donors could be used to deliver NO to the external sphincter systemically by oral, sublingual, or topical route. NO donors could relax the urethral sphincter either through an effect on its smooth muscle or striated muscle, or both. Because of the rich blood supply of the urethral sphincter, the oral or sublingual route would probably provide high local concentrations. Furthermore, the urethral sphincter is more sensitive to NO than is the detrusor, and NO donors can selectively relax the sphincter while having little effect on bladder function. If NO donors prove to be an effective therapy for DESD, then this could open the possibility for gene therapy with transfection of NOS into urethral muscle cells to provide a treatment for this condition.
Nitric oxide synthase/nitric oxide in diabetic cystopathy
In patients with diabetes mellitus, bladder capacity, detrusor contractility, and urinary flow rates are altered. Studies in diabetic rabbits showed that NOS activities increase in the urothelium, smooth muscle, and intramural neurons of the bladder neck and urethra [33] . However, cGMP formation in diabetic bladder neck and urethra is lower than in the control population. Despite the increase in NOS activity, NO-dependent urethral relaxation was impaired in diabetic individuals, along with impairment of the ability of the bladder outlet to relax during the voiding phase. Enhancing the NO-cGMP signal is therefore a therapeutic option for diabetic bladder dysfunction and deserves further exploration.
The effect of diabetes mellitus on urethral relaxation during reflex bladder contraction in rats was investigated and the results showed that L-arginine therapy, which augments urethral smooth muscle relaxation by increasing NO production, may be useful for partially restoring the urethral relaxation [34] . The role played by nNOS in chronic diabetic nephropathy and early cell-specific changes in NOS during diabetes-related bladder remodeling were also investigated [35,36 . ]. The results revealed early, time-dependent and cell-specific alterations in three isoforms of NOS, and formation of reactive nitrogen species in the bladder during remodeling.
Nitric oxide synthase/nitric oxide in interstitial cystitis and inflammatory disorders
In response to inflammation, the activity of iNOS is upregulated, production of NO is increased, and cGMP level is elevated. An increase in iNOS activity was observed in human bladder smooth muscle cells when these cells were treated with bacterial lipopolysaccharides and inflammatory cytokines [37] . These findings suggest that iNOS may be a mediator of bladder wall fibrotic response to chronic urinary tract infection, and iNOS inhibitors may be of therapeutic value in these patients. An investigation of cell death, proliferation, and iNOS immunoreactivity in rat urothelium after cyclophosphamide treatment revealed a correlation between iNOS immunoreactivity and an increase in apoptosis and proliferation of urothelial cells [38] . However, the functional role of iNOS in regulating apoptosis and proliferation of urothelial cells remains unclear. The role of iNOS and nNOS in the pathogenesis of cyclophosphamide-induced cystitis was investigated in rats and the results suggested that only iNOS is responsible for the production of inflammatory changes and cystitis [39] . NO produced by iNOS is also involved in urothelial damage and in the inflammatory events leading to hemorrhagic cystitis [40] . The induction of iNOS in the urothelium appears to depend on the synergistic effects of interleukin-1b and tumor necrosis factor-a.
In patients with interstitial cystitis, NOS activity in bladder biopsy is lower than in control individuals. This is associated with an elevation in cytokines such as interleukin-6 [3]. Intravesical administration of dimethyl sulfoxide stimulates the release of NO in bladder and relieves the symptoms of interstitial cystitis [3,4 . . ]. Oral L-arginine has been shown to improve symptoms in some patients with interstitial cystitis, but other patients failed to exhibit any symptomatic relief. In a randomized, double-blind, placebo-controlled trial of the efficacy of L-arginine in the treatment of interstitial cystitis [41] , oral L-arginine produced a statistically significant improvement in the interstitial cystitis symptoms index, but the effect was small. There are previous reports on increased as well as decreased levels of NO in patients with interstitial cystitis, and no consensus conclusion was reached on NO levels in the bladder of patients with interstitial cystitis. A recent study conducted in 17 patients with interstitial cystitis [42 . ] showed that all patients with classic interstitial cystitis had high levels of luminal NO in bladder, whereas none of the patients with nonulcerated interstitial cystitis had any significant increase in NO. Luminal NO probably originates from urothelial NOS because the activity of this enzyme is increased during inflammation process. These results also demonstrated that the two subtypes of interstitial cystitis represent separate entities.
Conclusion
NO has been recognized to play an important physiologic role during micturition and possibly in the pathophysiology of the lower urinary tract dysfunctions. Both in-vitro and in-vivo studies have suggested that NO serves as a neurotransmitter and cell mediator with a broad range of effects, including smooth muscle relaxation, in the lower urinary tract. Enhanced understanding of the role played by NO/NOS and the L-arginine-NO-cGMP pathway may allow us to identify novel pharmacologic targets for lower urinary tract disorders. There is need for further investigations to determine the precise function of NO in human lower urinary tract because most of the work so far was done in animal models.
